NCT00548340 - VEC-162 Study in Adult Patients With Primary Insomnia | Biotech Hunter

Enrollment

322

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

June 30, 2008

Conditions

Primary Insomnia

Interventions

DRUG

VEC-162 20 mg

20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

DRUG

Placebo

Placebo capsules, PO daily for five weeks

DRUG

VEC-162 50 mg

50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks

Trial Locations (35)

Unknown

Vanda Investigational Site, Birmingham

Vanda Investigational Site, Hot Springs

Vanda Investigational Site, Little Rock

Vanda Investigational Site, Anaheim

Vanda Investigational Site, Burbank

Vanda Investigational Site, Los Angeles

Vanda Investigational Site, San Diego

Vanda Investigational Site, Santa Monica

Vanda Investigational Site, Colorado Springs

Vanda Investigational Site, Hallandale

Vanda Investigational Site, Miami

Vanda Investigational Site, Naples

Vanda Investigational Site, Orlando

Vanda Investigational Site, Pembroke Pines

Vanda Investigational Site, St. Petersburg

Vanda Investigational Site, Atlanta

Vanda Investigational Site, Chicago

Vanda Investigational Site, Overland Park

Vanda Investigational Site, Crestview Hills

Vanda Investigational Site, Lexington

Vanda Investigational Site, Louisville

Vanda Investigational Site, Chevy Chase

Vanda Investigational Site, Newton

Vanda Investigational Site, Troy

Vanda Investigational Site, Chesterfield

Vanda Investigational Site, Las Vegas

Vanda Investigational Site, New York

Vanda Investigational Site, West Seneca

Vanda Investigational Site, Raleigh

Vanda Investigational Site, Beachwood

Vanda Investigational Site, Cincinnati

Vanda Investigational Site, Oklahoma City

Vanda Investigational Site, Columbia

Vanda Investigational Site, Austin

Vanda Investigational Site, Dallas